Sign In
Buy PETV
PetVivo Holdings . Common Stock Earnings Calls
| Release date | Jun 25, 2026 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Expected change | +/- 11.50% |
| Release date | Feb 17, 2026 |
| EPS estimate | - |
| EPS actual | -$0.0700 |
| Revenue estimate | - |
| Revenue actual | 286.108K |
| Release date | Nov 14, 2025 |
| EPS estimate | - |
| EPS actual | -$0.110 |
| Revenue estimate | - |
| Revenue actual | 303.284K |
| Release date | Aug 14, 2025 |
| EPS estimate | - |
| EPS actual | -$0.0900 |
| Revenue estimate | - |
| Revenue actual | 297.5K |
Last 4 Quarters for PetVivo Holdings . Common Stock
Below you can see how PETV performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $0.790 |
| EPS estimate | - |
| EPS actual | -$0.0900 |
| Date | Price |
|---|---|
| Aug 08, 2025 | $0.87 |
| Aug 11, 2025 | $0.86 |
| Aug 12, 2025 | $0.85 |
| Aug 13, 2025 | $0.82 |
| Aug 14, 2025 | $0.790 |
| Aug 15, 2025 | $0.81 |
| Aug 18, 2025 | $0.82 |
| Aug 19, 2025 | $0.84 |
| Aug 20, 2025 | $0.84 |
| 4 days before | -9.17% |
| 4 days after | 5.70% |
| On release day | 2.67% |
| Change in period | -4.00% |
| Release date | Nov 14, 2025 |
| Price on release | $1.33 |
| EPS estimate | - |
| EPS actual | -$0.110 |
| Date | Price |
|---|---|
| Nov 10, 2025 | $1.25 |
| Nov 11, 2025 | $1.40 |
| Nov 12, 2025 | $1.31 |
| Nov 13, 2025 | $1.34 |
| Nov 14, 2025 | $1.33 |
| Nov 17, 2025 | $1.15 |
| Nov 18, 2025 | $1.12 |
| Nov 19, 2025 | $1.10 |
| Nov 20, 2025 | $1.10 |
| 4 days before | 6.40% |
| 4 days after | -17.29% |
| On release day | -13.53% |
| Change in period | -12.00% |
| Release date | Feb 17, 2026 |
| Price on release | $0.650 |
| EPS estimate | - |
| EPS actual | -$0.0700 |
| Date | Price |
|---|---|
| Feb 10, 2026 | $0.80 |
| Feb 11, 2026 | $0.775 |
| Feb 12, 2026 | $0.780 |
| Feb 13, 2026 | $0.736 |
| Feb 17, 2026 | $0.650 |
| Feb 18, 2026 | $0.665 |
| Feb 19, 2026 | $0.680 |
| Feb 20, 2026 | $0.700 |
| Feb 23, 2026 | $0.700 |
| 4 days before | -18.74% |
| 4 days after | 7.68% |
| On release day | 2.29% |
| Change in period | -12.50% |
| Release date | Jun 25, 2026 |
| Price on release | - |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 28, 2026 | $0.798 |
| May 29, 2026 | $0.759 |
| Jun 01, 2026 | $0.700 |
| Jun 02, 2026 | $0.670 |
| Jun 03, 2026 | $0.726 |
PetVivo Holdings . Common Stock Earnings Call Transcript Summary of Q4 2025
PetVivo reported a productive fiscal 2025 with record revenue of approximately $1.1 million, a 17% year-over-year increase driven largely by expanded North American distribution (distributor sales up 31% to $958k, representing ~85% of revenue). Gross margin remained high at 87.8%. Operating expenses fell 21% to $9.1 million due to a company-wide cost reduction and restructuring program; R&D increased 13% to support clinical trials. Net loss improved 27% to $8.0 million ($0.39 per share) from $11.0 million the prior year. Cash and cash equivalents at year-end were $227,689 (unaudited); subsequent financing raised net proceeds of $4.7 million via a $5.0 million Series B convertible preferred offering, bringing pro forma cash to about $3.3 million. Commercial progress included expansion of the sales team, additions to distributor partners (Vedco, Clipper), entry into Mexico, and new strategic partnerships/licensing deals (VetStem for PrecisePRP, Digital Landia for pet AI, PiezoBioMembrane for biomaterials). Clinical evidence accumulation continues (canine elbow study, other published work) and management expects continued momentum and market penetration in fiscal 2026. The company filed a short extension for its Form 10-K; all financials discussed are preliminary and unaudited until filing.
